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Background/aim: To evaluate the effects of the storage/total International Prostate Symptom Score (s/T) ratio on the selection and
success of medical therapy in men with lower urinary tract symptoms (LUTS).
Materials and methods: A total of 54 men (>45 years of age) with moderate or severe LUTS were divided into 2 groups according
to the s/T ratio: Group 1 at <0.43 and Group 2 at >0.43. Tamsulosin (0.4 mg to Group 1) and tolterodine ER (4 mg to Group 2) were
administered. Patients were evaluated during the 1st and 3rd months of follow-up treatment.
Results: Thirty-seven (68.5%) and 17 (31.5%) patients were in Groups 1 and 2, respectively. The mean s/T ratios in Groups 1 and 2
increased to 0.38 ± 0.19 from 0.33 ± 0.08 (P = 0.03) and decreased to 0.54 ± 0.18 from 0.59 ± 0.1 (P = 0.17) during the 3rd month of
follow-up, respectively. The treatment success rates of Groups 1 and 2 were 88.4% and 75.7%, respectively. Nine unsuccessful cases were
treated with combination therapy and the treatment success was 86.6% at follow-up.
Conclusion: The s/T ratio is effective to determine symptom dominance in men with LUTS and can guide medical treatment selection
through better identification of symptoms.
Key words: Lower urinary tract symptoms, medical therapy, storage symptoms, antimuscarinics, α-blockers, treatment success,
International Prostate Symptom Score

1. Introduction
Lower urinary tract symptoms (LUTS) indicate the
pathologies of storage, voiding, and the postmicturition
phases of urination (1). The results of a large prevalence study
showed that storage symptoms such as urine frequency,
nocturia, urgency, and urge incontinence were more
prevalent (51.3%) than other LUTS in men (2). In recent
years, the paradigm shifted from the prostate to the bladder
for understanding, diagnosis, and treatment strategies of
LUTS in men. Accordingly, detrusor overactivity (DO)
and bladder outlet obstruction (BOO) play integral roles in
men with LUTS (3). Overactive bladder (OAB) symptoms
have more deteriorating effects on health-related quality
of life (QoL) than other LUTS (4,5). Furthermore, recent
studies have emphasized that combination therapy
(ComRx) with α-blockers and antimuscarinics had better
results in men with BOO who had mixed symptoms (6). In
contrast, LUTS in men are often still treated with therapies
targeting the prostate even if they have OAB symptoms (1).
* Correspondence: acarcenk@hotmail.com
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Although DO and OAB symptoms may develop secondary
to BOO in men, they also may occur independently (7,8).
Determination of the dominating pathology in the clinical
scenario of patients with LUTS is a major concern in opting
for medical therapy.
The International Prostate Symptom Score (IPSS) is
the most relevant tool to assess the severity of LUTS (9).
Three of the 7 questions evaluate storage symptoms and
1 evaluates QoL. The major disadvantage of the IPSS total
score is its inability to determine potential etiologies.
Urodynamic evaluation is the gold standard but it is an
invasive method. There is no widely accepted noninvasive
diagnostic test to identify dominant symptoms of storage
or voiding in LUTS. Recently, the importance of the
IPSS has become well recognized and some authors have
published data that constitute different IPSS ratios (10,11).
The objective of the present study was to evaluate the
effect of the storage/total IPSS ratio (s/T) as a new tool to
individualize medical therapy in men with LUTS.
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2. Materials and methods
2.1. Patient selection
A total of 54 men (>45 years of age) with moderate or severe
LUTS on the IPSS were prospectively included in this study.
Exclusion criteria were the diagnoses of any lower urinary
tract condition other than prostatic enlargement (prostate
cancer, surgery, infection, stones, strictures, neurological
diseases, etc.), previous prostatic surgery, and medication
for BOO and/or DO. The institutional review board and
ethics committee approved the study protocol. Prostatespecific antigen (PSA), IPSS, uroflowmetry, prostate
volume, postvoiding residual urine volume (PVR), and
pressure flow study (PFS) were measured in all patients.
All patients were further divided into 2 groups
according to the s/T ratio obtained by dividing the total
score of all questions examining storage function in the
IPSS (2nd, 4th, and 7th) by the total score of all questions
(15/35 = 0.43). Patients were grouped by s/T cut-off value of
0.43 (Group 1 at <0.43 and Group 2 at >0.43). Tamsulosin
(0.4 mg, once daily per os) was administered in Group 1,
while tolterodine ER (TER; 4 mg, once daily per os) was
administered in Group 2. Patients were evaluated during
the 1st and 3rd months of follow-up treatment. Treatment
success was defined as symptom improvement by IPSS of
≥4 points on 2 consecutive visits, 1 point improvement of
QoL score, and/or any rise of maximum flow rate (Qmax)
(12,13). A treatment algorithm according to the design of
the study is shown in Figure 1. ComRx was administered
in case of treatment failure during the 1st month of followup treatment. Treatment success of ComRx was evaluated
1 month after starting the ComRx treatment as stated
above. If a patient’s Qmax was <8 mL/s and PVR was >200
mL after initial treatment, transurethral resection of the

prostate (TURP) was performed and these patients were
excluded from the study.
2.2. Pressure flow studies
All patients underwent PFS, and the bladder outlet
obstruction index (BOOI) and bladder contractility index
(BCI) were calculated using the following formulas:
BOOI: detrusor pressure at maximum flow rate
(PdetQmax) – 2 × maximum flow rate (Qmax).
BCI: PdetQmax + 5 × Qmax.
Patients were categorized into 3 groups with reference
to the BOOI score: obstructed (BOOI of >20), equivocal
(BOOI = 20–40), or unobstructed (BOOI of <20). Using
BCI, patients were categorized into groups with strong
(BCI of >100), normal (BCI = 100–150), and weak (BCI
of <100) contractility.
2.3. Statistical analysis
Statistical analyses were performed using SPSS 17.0 (SPSS
Inc., Chicago, IL, USA). The Mann–Whitney U test and
chi-squared test were used to compare the 2 groups. The
Wilcoxon rank test and logistic regression analysis were
performed to determine treatment success. P < 0.05 was
accepted as statistically significant.
3. Results
The mean age of the patients was 62.1 ± 8 years. There were
37 (68.5%) patients in Group 1 and 17 (31.5%) in Group
2. The mean s/T ratios of Groups 1 and 2 were 0.33 ± 0.08
and 0.59 ± 0.1, respectively. No statistically significant
difference was found in the pretreatment variables between
the groups for the s/T ratios (Table 1). Five (13.5%) patients
in Group 1 and 8 (47%) in Group 2 had statistically
significant differences in urge urinary incontinence (P
= 0.01). When we compared the pretreatment variables
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Figure 1. Treatment algorithm according to design of the study.
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Table 1. Comparison of patient pretreatment variables according to s/T ratio.
Group 1
(s/T ratio of <0.43)
(n = 37)
(mean ± SD)

Group 2
(s/T ratio of >0.43)
(n = 17)
(mean ± SD)

P-value

Age

61 ± 7.59

60.9 ± 8.8

0.96

Total IPSS

17.8 ± 5.84

16.2 ± 8.14

0.44

QoL score

3.52 ± 1.1

3.53 ± 1.3

0.92

1.5 ± 1.06

1.62 ± 1.33

0.744

Prostate volume (cm )

32.9 ± 16.5

32 ± 15.5

0.859

Maximum cystometric capacity (mL)

381.14 ± 77.4

262.8 ± 143.3

0.006

Qmax (mL/s)

11.9 ± 3.77

15.1 ± 6.18

0.08

Maximum detrusor pressure during voiding phase

69 ± 27.4

62.7 ± 16

0.47

Maximum detrusor pressure during maximum flow

50.9 ± 25

46.8 ± 12.1

0.6

Voiding volume (mL)

282 ± 135.8

276 ± 141.8

0.891

Residual volume (mL)

50.3 ± 41.9

44.7 ± 57

0.7

Total PSA (ng/mL)
3

between the 2 groups, only the maximum cystometric
capacity was higher in Group 1 (P < 0.001) (Table 1).
Treatment success of Groups 1 and 2 was 88.4% and
75.7%, respectively. The data from the baseline and the 1st
and 3rd months’ follow-up variables in Groups 1 and 2 are
shown in Figures 2 and 3, respectively. The mean s/T ratios
in Groups 1 and 2 changed from 0.33 ± 0.08 to 0.38 ± 0.19
(P = 0.03) and from 0.59 ± 0.1 to 0.54 ± 0.18 (P = 0.17) in

the 3rd month of follow-up treatment, respectively. When
we compared the data from each group in terms of total
IPSS, storage and voiding scores, QoL score, and Qmax
(mL/s) in the follow-up periods, all parameters were
statistically different from baseline values, except for Qmax
in the 1st month of follow-up for Group 2 (Figures 2 and
3). Significant decreases were found in total IPSS (–7.6),
along with an improvement in QoL score (–1.6), a slightly

Total
IPSS

11.9

Storage Voiding Score

3.5

QoL

Qmax

Figure 2. Mean values of IPSS, storage and voiding subscale
scores, QoL, and Qmax (mL/s) in Group 1 during the follow-up
period.
*: Statistically significant difference was found when comparing
1st month follow-up values with baseline values.
†: Statistically significant difference was found when comparing
3rd month follow-up values with baseline values.
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Figure 3. Mean values of IPSS, storage and voiding subscale
scores, QoL, and Qmax (mL/s) in Group 2 during the follow-up
period.
*: Statistically significant difference was found when comparing
1st month follow-up values with baseline values.
†: Statistically significant difference was found when comparing
3rd month follow-up values with baseline values.
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increased Qmax ( +1.33 mL/s), and a minimally decreased
PVR (–22.6 mL) in Group 2 during the 3rd month of
follow-up. The PVR of unsuccessful cases in the 1st month
of follow-up treatment (95 ± 65 mL) was significantly
higher than in the successful counterparts (42 ± 36.2 mL)
in Group 1 (P = 0.007). The multivariate analysis showed
that only PVR was identified as an independent predictive
factor affecting treatment success in Group 1 (P = 0.004;
odds ratio = 1.05, range: 1.01–1.07). There was no increase
in the PVR of Group 2 during the 1st and 3rd months of
follow-up treatment (P > 0.05).
The calculated BOOI and BCI values of Groups 1 and
2 according to PFS are shown in Table 2. Regarding the
baseline PFS, BOOI and BCI values of the patients did not
show any significant difference between the groups (P =
0.324, P = 0.153; data not shown in Table 2).
Five patients in Group 1 and 4 patients in Group 2 did
not respond to first-line treatments. TURP was performed
in 2 of 5 patients in Group 1. Seven of 9 nonresponsive
patients received ComRx and the treatment success rate
was 86.6% (6 of 7 patients) during the 1st month of followup treatment. The mean s/T ratio was 0.47 in the ComRx
group. There was a decrease of 7.8 in IPSS and 1.88 in QoL,
and an increase of 3.03 mL/s in Qmax with ComRx.
The most common adverse event was mild xerostomia,
reported by 18% of the patients (3 of 17) receiving
antimuscarinics. No serious adverse event was reported
to prompt drug withdrawal and no urinary retention was
observed in either group.
4. Discussion
Epidemiological studies have shown that 60% of men
in the general population complained about at least 1
type of LUTS, whereas 48.4% of men with LUTS had
only OAB symptoms and 35.2% had mixed symptoms,
including voiding, storage, and postmicturition symptoms

(2). Although treating the prostate gland has been an
accepted method in LUTS management, the presence and
predominance of OAB symptoms in bothersome LUTS
seems to be an important issue. The determination of
predominant symptoms of LUTS in the clinical scenario
with noninvasive diagnostic tools is challenging.
α-Blockers are widely accepted as the first-line treatment
for men with LUTS suggestive of BOO. Although there
are controversies concerning treatment success criteria
of α-blockers in the literature, studies have reported that
56%–80% of patients had improved symptoms using
α-blockers (12,14). In the present study, treatment success
with tamsulosin monotherapy was 88.4%, which was
higher than in previous studies. We think that our success
rate was related to the selection of appropriate patients
who would likely benefit from tamsulosin monotherapy.
Additionally, a significant increase in the mean s/T ratio
(0.33 to 0.38) indicated that tamsulosin improved voiding
symptoms rather than storage symptoms.
Although antimuscarinics reduce DO and are
indicated for the treatment of OAB, until recently, many
men have been only prescribed antimuscarinics for
persistent OAB symptoms following prostatic surgery
(8). Antimuscarinic therapy in men with LUTS has
traditionally been avoided due to an increased risk of
acute urinary retention in BOO cases. However, primary
studies (15,16) and post hoc analyses (17,18) suggested
that antimuscarinics were not associated with an increased
incidence of urinary retention and substantial increase
of PVR in men with OAB with or without other LUTS.
Kaplan et al. (16) evaluated the effectiveness of TER
monotherapy in men with LUTS who did not respond to
initial α-blocker treatment and found significant changes
in total IPSS (–6.1), peak urinary flow rate ( +1.9 mL/s),
and PVR (–22 mL) after 6 months of TER monotherapy.
They also reported that the storage and voiding scores

Table 2. Comparisons of the BOO and BC indexes of patients in Groups 1 and 2 according to success of the treatments
at 3rd month of follow-up.

Group 1
(n = 37)

Group 2
(n = 17)

BOOI
subgroups

BOO index,
n (%)

BCI
subgroups

BC index,
n (%)

<20

15 (40.5)

<100

34 (45.3)

20–40

18 (24)

100–150

36 (48)

>40

27 (36)

>150

5 (6.7)

<20

21(63.6)

<100

3 (9.1)

20–40

9 (27.2)

100–150

27 (81.8)

>40

3 (9.2)

>150

3 (9.1)

P-value*

0.101

0.143

P-value*

0.050

0.247

*: P-values indicate the comparison of each index in each group according to success of treatment.
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of patients significantly decreased after treatment and
concluded that TER is an effective and well-tolerated
therapy and can be used initially or after failed treatment
with α-blockers. Similarly, we found a significant decrease
in total IPSS (–7.6), an improvement in QoL score (–1.6),
a slightly increased Qmax (+1.33 mL/s), and a minimally
decreased PVR (–22.6 mL) in Group 2 during the 3rd
month of follow-up. Additionally, the s/T ratio decreased
from 0.59 to 0.54. Treatment success of this group was
75.7% with TER monotherapy. Acute urinary retention
and an increase in PVR were not detected. Hence, TER
monotherapy seems to be safe, at least over a 12-week
period, in patients with BOO and DO.
Recently, several groups have evaluated the efficacy
and tolerability of ComRx in men with OAB and BOO. A
multicenter randomized trial was conducted to investigate
the implications of TER and tamsulosin (TIMES study) in
men with LUTS (15), whereas others performed subgroup
analyses using PSA, prostate size, and IPSS (6,19,20).
Treatment success was defined as the patients’ perceptions
of treatment benefit and was reported as 61.7% in placebo,
65.1% in TER, 70.8% in tamsulosin, and 80% in ComRx
therapies. The s/T ratios of their groups were 0.51, 0.5, 0.51,
and 0.5, respectively. Improved bothersome symptoms
with ComRx, rather than tamsulosin monotherapy, might
be explained by the dominance of storage symptoms in
that group. In contrast, the authors reported unsuccessful
treatment results with TER monotherapy compared with
a placebo, but the greater treatment success obtained in
our study appeared to be related to the higher s/T ratio
(0.59) in Group 2 than in the TER group of the TIMES
study. Chapple et al. (21) evaluated the effectiveness of
added TER to previous unsuccessful α-blocker treatment
in men with prominent storage symptoms suggestive of
OAB and found that additional TER caused significant
improvements in diary variables, IPSS storage scores, and
bothersome symptoms. The s/T ratios of the placebo and
TER groups were 0.5 and 0.49, respectively. Regarding
this ratio, their study group had predominant storage
symptoms and, with respect to our hypothesis, additional
TER treatment was successful as expected.
A prospective randomized study evaluated the efficacy
and safety of propiverine combined with doxazosin in
urodynamically confirmed BOO patients with OAB
symptoms and concluded that ComRx was more effective
than doxazosin monotherapy (12). The calculated s/T ratio
was 0.41 in the doxazosin group and 0.43 in the ComRx
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group; the patient groups had nearly equal voiding and
storage symptoms according to our s/T cut-off value and
2/3 of the patients had simultaneous BOO after urodynamic
studies. Therefore, successful therapy was anticipated with
doxazosin. Better results with ComRx might be explained
by the presence of OAB symptoms. According to the s/T
ratio, the treatment success rates in the present study were
88.4%, 75.7%, and 86.6%, respectively, for tamsulosin,
TER, and ComRx. In other words, we successfully treated
84.2% of 54 patients who were admitted to our clinic with
first-line therapy. The success rate reached 96.2% when
the ComRx results were added. Our results indicated that
most patients were successfully treated with any kind of
medical therapy after the 1st month of follow-up using
the s/T ratio. We suggest that ComRx should be initially
prescribed in men with mixed symptoms.
Song et al. evaluated voiding and storage functions
with respect to bladder outlet obstruction grade and
contractility in 232 patients treated with alfuzosin. They
did not find any correlation between treatment success and
the indexes (BOOI and BCI) (22). Similarly, neither the
obstruction grade nor the contractility status in Groups 1
and 2 impacted the treatment success in our study (P =
0.311 and 0.466, respectively; data not shown in a table).
These data show that urodynamic parameters do not
predict the baseline symptom severity and improvement
after treatment.
The major limitation of the present study was an
inadequate cohort number to determine a definitive s/T
cut-off value and the lack of a placebo group. Although
the underlying pathologies of LUTS are complex, the s/T
ratio can predict the underlying pathology and it allows
determination of the patients who would benefit from
antimuscarinic administration. On the other hand, we
suggest that different cut-off values should be defined for
selecting first-line medical treatment including α-blockers,
antimuscarinics, or ComRx. The other shortcoming of
our study was the lack of using a specific validated OAB
questionnaire in the evaluation of the patients.
In conclusion, the s/T ratio may affect selection of
medical treatment by better identifying storage or voiding
symptoms and may improve success rates by preventing
over- or underutilization of medications. We suggest
initially administering antimuscarinic monotherapy in
men with LUTS using the s/T ratio. However, the s/T
cut-off value for medical treatment selection should be
confirmed in a large prospective randomized study.
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